ARA-290 (cibinetide): doses reported in published research

Sources checked 2026-10-07 · 5 cited studies (4 human, 1 animal, 0 cell culture) · 3 registered trials

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the structure of erythropoietin that does not stimulate red-cell production. It has been tested in small human trials, mainly in sarcoidosis-associated small-fiber neuropathy.

Human data: randomized placebo-controlled trials in sarcoidosis (22-64 participants) and a study in 36 healthy volunteers, plus registered trials.

Studies in people (4)

Human 22 adults with sarcoidosis and small-fiber neuropathy, randomized double-blind placebo-controlled pilot (12 active, 10 placebo)

Dose as reported: 2 mg
Route: Intravenous
Frequency / duration: Three times weekly for 4 weeks

Source wording: consisting of three times weekly intravenous dosing of ARA 290 (2 mg; n = 12) or placebo (n = 10) for 4 wks. A total of 22 patients diagnosed with sarcoidosis

Heij L, Niesters M, Swartjes M et al.. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012. PubMed PMID 23168581 ↗

Human 64 adults with sarcoidosis-associated small nerve fiber loss, phase 2b randomized trial

Dose as reported: 1, 4 or 8 mg/day (separate groups)
Route: Not stated in the abstract (subcutaneous per registry record NCT02039687)
Frequency / duration: 28 days

Source wording: This phase 2b, 28-day, randomized trial of 64 subjects Cibinetide (1, 4, or 8 mg/day) was compared to placebo.

Culver DA, Dahan A, Bajorunas D et al.. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci 2017. PubMed PMID 28475703 ↗

Human Adults with sarcoidosis and small nerve fiber loss, blinded placebo-controlled trial

Dose as reported: Not stated in the abstract
Route: Subcutaneous
Frequency / duration: Daily for 28 days

Source wording: 28 d of daily subcutaneous administration of ARA 290

Dahan A, Dunne A, Swartjes M et al.. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013. PubMed PMID 24136731 ↗

Human 36 healthy volunteers, randomized double-blind placebo-controlled

Dose as reported: 2 mg
Route: Intravenous, per registry record NCT02070783 (not stated in the abstract)
Frequency / duration: Single dose

Source wording: Healthy participants (N=36) received ARA290 (2mg) or placebo

Cerit H, Veer IM, Dahan A et al.. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol 2015. PubMed PMID 26431906 ↗

Animal studies (1)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal Rats (experimental autoimmune encephalomyelitis)

Dose as reported: 35 or 70 µg/kg
Route: Intraperitoneal
Frequency / duration: Once daily from day 7 to day 18 or day 9 to day 19

Source wording: Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily

Chen H, Luo B, Yang X et al.. Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol 2014. PubMed PMID 24518674 ↗

Registered trials (3)

From ClinicalTrials.gov records. Registry entries describe planned designs; they are not published results.

Registered trial (no published results) Adults with sarcoidosis, phase 2; completed, results posted

Dose as reported: 1, 4 or 8 mg per day (separate arms)
Route: Subcutaneous
Frequency / duration: 28 consecutive days

Source wording: 1 mg ARA 290 administered subcutaneously for 28 consecutive days 4 mg ARA 290 administered subcutaneously for 28 consecutive days 8 mg ARA 290 administered subcutaneously for 28 consecutive days

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. ClinicalTrials.gov registry record. NCT02039687 ↗

Registered trial (no published results) Healthy volunteers, phase 1/2; completed, no results posted

Dose as reported: 2 mg
Route: Intravenous
Frequency / duration: Single dose

Source wording: intravenous injection with 2 mg ARA290 (single dosage).

Cognitive and Neural Effects of ARA290. ClinicalTrials.gov registry record. NCT02070783 ↗

Registered trial (no published results) Adults with diabetic macular oedema, phase 2; terminated, no results posted

Dose as reported: 4 mg
Route: Subcutaneous
Frequency / duration: Daily for 12 weeks (84 days)

Source wording: Subcutaneous daily injection of ARA 290 at a dose of 4mg for 12 weeks. over an 84 day period

The Use of ARA290 for the Treatment of Diabetic Macular Oedema. ClinicalTrials.gov registry record. NCT06626971 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.